Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

ClinicalTrials.gov ID: NCT05393895

Public ClinicalTrials.gov record NCT05393895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.

Study identification

NCT ID
NCT05393895
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Orasis Pharmaceuticals Ltd.
Industry
Enrollment
178 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 21, 2022
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update posted
Jun 10, 2025

2022

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Orasis Investigative Site Newport Beach California 92663
Orasis Investigative Site Petaluma California 94954
Orasis Investigative Site Colorado Springs Colorado 80907
Orasis Investigative Site Danbury Connecticut 06810
Orasis Investigative Site Rock Island Illinois 61201
Orasis Investigative Site Overland Park Kansas 66210
Orasis Investigative Site Elizabeth City North Carolina 27909
Orasis Investigative Site Fargo North Dakota 58103
Orasis Investigative Site Cranberry Township Pennsylvania 16066
Orasis Investigative Site Kingston Pennsylvania 18704
Orasis Investigative Site Memphis Tennessee 38119
Orasis Investigative Site Cedar Park Texas 78613

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05393895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2025 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05393895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →